Rigel to Present at the J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 10, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, is scheduled to present a company overview at the 40th Annual J.P. Morgan Healthcare Conference at 10:30 a.m. ET on Wednesday, January 12, 2022.
To access the live and subsequently archived webcast, go to the Investor Relations section of the company's website at www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.
Fostamatinib is currently being studied in a Phase 3 clinical trial (NCT03764618) for the treatment of warm autoimmune hemolytic anemia (wAIHA)1; a Phase 3 clinical trial (NCT04629703) for the treatment of hospitalized high-risk patients with mild-to-moderate COVID-191; an NIH/NHLBI-funded Phase 3 ACTIV-4 Host Tissue Study (NCT04924660) for the treatment of COVID-19 in hospitalized patients on oxygen therapy, and a Phase 2 clinical trial (NCT04581954) for the treatment of COVID-19 being conducted by Imperial College London.
Rigel's other clinical programs include its interleukin receptor-associated kinase (IRAK) inhibitor program, and a receptor-interacting serine/threonine-protein kinase (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, Rigel has product candidates in development with partners BerGenBio ASA, and Daiichi Sankyo.
Please see www.TAVALISSE.com for full Prescribing Information.
1The product for this use or indication is investigational and has not been proven safe or effective by any regulatory authority.
View original content to download multimedia:https://www.prnewswire.com/news-releases/rigel-to-present-at-the-jp-morgan-healthcare-conference-301457580.html
SOURCE Rigel Pharmaceuticals, Inc.
Company Codes: NASDAQ-NMS:RIGL